2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic

Program: Oral Abstract Session
Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - R06-R09
Technology and Procedures, Imaging, Omics Technologies, Computational Biology, Gene Editing, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Study Population, Human, Animal Model
PAPER

216 Periodic pauses in cell mass accumulation sustain clonal fitness in leukemia

Zhangliang Cheng, BSc, Ruoyi Shi2, Kohei Kume, PhD3, Siyi Chen4, Yujin Bao5, Mark E Robinson, PhD6, Song Wu, PhD7, Richard Kim8, Yanzhi Feng, BS9, Ka-Won Kang10, Ruifeng Sun, BS11, Kadriye Nehir Cosgun, PhD12, Andrew Martins13, Joerg Bewersdorf, PhD14, Min Wu15, Markus Müschen, MD-PhD16
1 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Immunobiology, New Haven, Connecticut, United States
2 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
3 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
4 Department of Immunobiology, New Haven, Connecticut, United States
5 Department of Cell Biology, New Haven, Connecticut, United States
6 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
7 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
8 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
9 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
10 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
11 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
12 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
13 Department of Immunobiology, New Haven, Connecticut, United States
14 Department of Cell Biology, New Haven, Connecticut, United States
15 Department of Cell Biology, New Haven, Connecticut, United States
16 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Immunobiology, New Haven, Connecticut, United States

Background and Significance. The hematopoietic system operates near the lower limit of mammalian cell size, necessitating stringent control of cell growth and biomass accumulation. Yet acute leukemias arise from some of the smallest somatic cells while sustaining extraordinary proliferative capacity. Here, we investigated how leukemia cells coordinate biomass accumulation with the competing demands of small cell size and rapid proliferation.

Results. Quiescence and proliferation are generally considered mutually exclusive states in hematopoietic stem cells and leukemia. Here, we unexpectedly identified rapid oscillatory expression of the master hematopoietic regulators MYC and BCL6, enabling leukemia cells to alternate repeatedly between anabolic growth and quiescent metabolic programs within a single cell cycle.

Transcriptomic analyses of AML and normal hematopoietic development identified MYC and BCL6 as reciprocal markers of proliferative and quiescent states. To visualize their dynamics, we generated endogenous dual MYC-BCL6 fluorescent reporter models by CRISPR knock-in, including patient-derived leukemia xenografts expressing MYC-mNeonGreen-dTAG and BCL6-mScarlet. Long-term quantitative live-cell imaging revealed recurrent MYC-BCL6 oscillations with an average period of approximately four hours, allowing multiple transitions within a single cell cycle. Oscillations were observed in 30-80% of cells across genetically acute myeloid leukemias, including FLT3-ITD-, JAK2- and JAK3-fusions, BCR::ABL1- and KRAS-G12D-driven acute leukemias.

To define the functional significance of each phase, we combined rapid MYC degradation using an inducible degron with pharmacologic BCL6 degradation using a PROTAC, enabling acute manipulation of either transcription factor within 30 minutes. MYC depletion suppressed protein synthesis, glycolysis, and oxidative phosphorylation while enhancing autophagic flux, whereas BCL6 degradation produced the opposite metabolic effects. Consistently, transcriptomic and metabolomic analyses showed that MYC+/BCL6− cells exhibited increased cell size, glycolytic flux, and anabolic activity, whereas MYC−/BCL6+ cells displayed reduced cell size, autophagy, and phosphatidylethanolamine synthesis. Simultaneous label-free holotomography and fluorescence imaging demonstrated rapid biomass accumulation during MYC-high phases followed by transient growth arrest during BCL6-high phases, revealing a previously unrecognized stepwise pattern of leukemia cell growth.

We next examined whether this oscillatory plasticity contributes to leukemia stem-cell function. Cells enriched for repeated MYC-BCL6 oscillations exhibited a five-fold increase in leukemia-initiating cell frequency compared with cells maintained in the MYC-high state. Conversely, pharmacologic blockade of entry into the BCL6 phase reduced leukemia stem-cell frequency by nearly one order of magnitude, demonstrating that dynamic transitions, rather than either state alone, are required for efficient leukemia initiation. Consistent with these findings, treatment with a BCL6-targeting PROTAC impaired leukemia initiation and reduced clonal fitness in patient-derived xenografts.

Genome-wide CRISPR screening identified STAT5 as the central regulator of MYC-BCL6 oscillation through oncogenic kinase signaling coupled to a CISH-SOCS2 negative-feedback circuit. Pharmacologic STAT5 inhibition synchronized cells in the BCL6-high state, whereas STAT5 activation synchronized cells in the MYC-high state. The E3 ligases FBXW7 and FBXO11 constrained oscillation amplitude by limiting MYC- and BCL6-dominant phases, respectively. Accordingly, in tyrosine kinase-driven leukemias, MYC promoted proliferation and increased cell size, whereas tyrosine kinase inhibition induced BCL6-dependent quiescence and cell shrinkage.

Conclusions. These findings identify MYC-BCL6 oscillation as a previously unrecognized dynamic cell-state program coupling oncogenic signaling to metabolic plasticity, stepwise biomass accumulation, and leukemia stem-cell function. Rather than sustaining constitutive signaling, oncogenic kinase pathways generate reversible transitions between growth and recovery phases that promote malignant fitness. Given the ongoing clinical evaluation of BCL6 degraders, targeting the BCL6-dependent phase may provide a therapeutic strategy to eliminate leukemia-initiating and drug-resistant cells.

Zhangliang Cheng, BSc: No relevant conflicts of interest to declare.